Tumor genetics is the investigation of genetic changes that cause cancer development, tumor growth and progression, and response to therapy. The session "Tumor Genetics" is dedicated to learning how mutations, chromosomal alterations, and hereditary influences affect tumor behavior and inform individualized treatment approaches.".
The major constituents of tumor genetics are oncogenes, tumor suppressor genes, gene fusions, copy number variations, and epigenetic alterations. These genetic alterations regulate cell proliferation, apoptosis, metastasis, and therapy responsiveness. Clinicians, by examining the tumor genetic profiles, can determine actionable mutations, predict disease, and choose targeted therapies for individualized patients.
The meeting delves into futuristic technologies like next-generation sequencing, whole-genome sequencing, and exome sequencing, and liquid biopsy for large-scale genetic profiling. Bioinformatic integration and molecular diagnostics make it possible to monitor tumor development in real time, detect resistance early on, and tailor treatment accordingly. Furthermore, knowledge of hereditary cancer syndromes helps to assess the risk and prevention protocols for high-risk individuals.
Participants will learn about the biology, clinical use, and future research in tumor genetics. This session highlights how genetic knowledge fuel precision oncology, maximize the selection of therapy, enhance patient outcomes, and lead to innovative cancer therapies based on personalized genetic data.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
